Compare PLBC & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBC | BNTC |
|---|---|---|
| Founded | 1980 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.9M | 360.7M |
| IPO Year | 2002 | 2020 |
| Metric | PLBC | BNTC |
|---|---|---|
| Price | $57.23 | $13.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $57.67 | $27.67 |
| AVG Volume (30 Days) | 64.2K | ★ 81.2K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ 1.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.59 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | $40.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.70 | $9.85 |
| 52 Week High | $57.51 | $16.76 |
| Indicator | PLBC | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 68.07 | 67.23 |
| Support Level | $50.86 | $12.79 |
| Resistance Level | $57.51 | $13.40 |
| Average True Range (ATR) | 1.71 | 0.70 |
| MACD | 0.12 | 0.26 |
| Stochastic Oscillator | 96.30 | 92.88 |
Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.